Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC.
PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models.
RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414).
CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
ESMO open - 8(2023), 1 vom: 15. Feb., Seite 100747 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gampenrieder, S P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HER2-low |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 24.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2022.100747 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350750327 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350750327 | ||
| 003 | DE-627 | ||
| 005 | 20231226045711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2022.100747 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350750327 | ||
| 035 | |a (NLM)36563519 | ||
| 035 | |a (PII)S2059-7029(22)00381-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gampenrieder, S P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 24.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC | ||
| 520 | |a PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models | ||
| 520 | |a RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414) | ||
| 520 | |a CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HER2-low | |
| 650 | 4 | |a OS | |
| 650 | 4 | |a metastatic | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a real-world data | |
| 650 | 4 | |a triple-negative breast cancer | |
| 700 | 1 | |a Dezentjé, V |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, M |e verfasserin |4 aut | |
| 700 | 1 | |a de Nonneville, A |e verfasserin |4 aut | |
| 700 | 1 | |a Marhold, M |e verfasserin |4 aut | |
| 700 | 1 | |a Le Du, F |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés Salgado, A |e verfasserin |4 aut | |
| 700 | 1 | |a Alpuim Costa, D |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz Batista, M |e verfasserin |4 aut | |
| 700 | 1 | |a Chic Ruché, N |e verfasserin |4 aut | |
| 700 | 1 | |a Tinchon, C |e verfasserin |4 aut | |
| 700 | 1 | |a Petzer, A |e verfasserin |4 aut | |
| 700 | 1 | |a Blondeaux, E |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, L |e verfasserin |4 aut | |
| 700 | 1 | |a Targato, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bertucci, F |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, A |e verfasserin |4 aut | |
| 700 | 1 | |a Viret, F |e verfasserin |4 aut | |
| 700 | 1 | |a Bartsch, R |e verfasserin |4 aut | |
| 700 | 1 | |a Mannsbart, C |e verfasserin |4 aut | |
| 700 | 1 | |a Deleuze, A |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, L |e verfasserin |4 aut | |
| 700 | 1 | |a Saavedra Serrano, C |e verfasserin |4 aut | |
| 700 | 1 | |a Gion Cortés, M |e verfasserin |4 aut | |
| 700 | 1 | |a Sampaio-Alves, M |e verfasserin |4 aut | |
| 700 | 1 | |a Vitorino, M |e verfasserin |4 aut | |
| 700 | 1 | |a Pecen, L |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, C |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, N |e verfasserin |4 aut | |
| 700 | 1 | |a Rinnerthaler, G |e verfasserin |4 aut | |
| 700 | 1 | |a Greil, R |e verfasserin |4 aut | |
| 700 | 0 | |a AGMT Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Balic, Marija |e investigator |4 oth | |
| 700 | 1 | |a Heibl, Sonja |e investigator |4 oth | |
| 700 | 1 | |a Zabernigg, August Felix |e investigator |4 oth | |
| 700 | 1 | |a Egle, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Sandholzer, Margit |e investigator |4 oth | |
| 700 | 1 | |a Roitner, Florian |e investigator |4 oth | |
| 700 | 1 | |a Andel, Johannes |e investigator |4 oth | |
| 700 | 1 | |a Pichler, Petra |e investigator |4 oth | |
| 700 | 1 | |a Hager, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Knauer, Michael |e investigator |4 oth | |
| 700 | 1 | |a Hubalek, Michael |e investigator |4 oth | |
| 700 | 1 | |a Bighin, Claudia |e investigator |4 oth | |
| 700 | 1 | |a De Laurentiis, Michelino |e investigator |4 oth | |
| 700 | 1 | |a De Placido, Sabino |e investigator |4 oth | |
| 700 | 1 | |a Puglisi, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Boni, Luca |e investigator |4 oth | |
| 700 | 1 | |a de Gregorio, Amelie |e investigator |4 oth | |
| 700 | 1 | |a Degenhardt, Tom |e investigator |4 oth | |
| 700 | 1 | |a Formisano, Luigi |e investigator |4 oth | |
| 700 | 1 | |a Beelen, Karin |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Fitzpatrick, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Dieras, Veronique |e investigator |4 oth | |
| 700 | 1 | |a Muller, Volkmar |e investigator |4 oth | |
| 700 | 1 | |a Gennari, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Linn, Sabine |e investigator |4 oth | |
| 700 | 1 | |a Braga, Sofia |e investigator |4 oth | |
| 700 | 1 | |a Cortes, Javier |e investigator |4 oth | |
| 700 | 1 | |a Palmieri, Carlo |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 8(2023), 1 vom: 15. Feb., Seite 100747 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |g day:15 |g month:02 |g pages:100747 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2022.100747 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 |b 15 |c 02 |h 100747 | ||